Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
Alternative names
treggraft (Orca-T) (2 trials)
allogeneic donor-derived t-cells transduced with bivalent lentiviral vector (cd19/cd22-bbz) chimeric antigen receptor (car) (1 trial)
autologous cd34+ cells (2 trials)
autologous regulatory t cells (1 trial)
cyclophosphamide (cytoxan) (1 trial)
Filgrastim (neupogen) (1 trial)
fludarabine (fludara) (1 trial)
melphalan (alkeran) (1 trial)
plerixafor (mozobil) (1 trial)
tacrolimus (prograf) (1 trial)
Leukemia (Phase 1)
Leukemia, Lymphoid (Phase 1)
Myelodysplastic Syndromes (Phase 1)
Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 1)
Preleukemia (Phase 1)
Trials (4 total)
Trial APIs (10 total)